



## **Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference**

May 28, 2025

REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Goldman Sachs 46<sup>th</sup> Annual Global Health Care Conference in Miami on Wednesday, June 11, 2025, at 7:00 AM PT / 10:00 AM ET.

A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at <https://investors.pulmonx.com/>.

### **About Pulmonx Corporation**

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr<sup>®</sup> Endobronchial Valve, Chartis<sup>®</sup> Pulmonary Assessment System, LungTrax<sup>™</sup> Platform, and Strat<sup>®</sup> Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a "breakthrough device." The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit [www.Pulmonx.com](http://www.Pulmonx.com).

Pulmonx<sup>®</sup>, AeriSeal<sup>®</sup>, Chartis<sup>®</sup>, StratX<sup>®</sup>, and Zephyr<sup>®</sup> are registered trademarks and LungTraX<sup>™</sup> is a trademark of Pulmonx Corporation.

### **Investor Contact**

Jeremy Feffer

LifeSci Advisors

[jfeffer@lifesciadvisors.com](mailto:jfeffer@lifesciadvisors.com)